on Monday announced new research confirming the company's ability to detect and identify Group B streptococcus in four to six hours -- 12 to 18 times more quickly than traditional detection methods, it says.
NanoLogix, which is awaiting FDA approval for its BioNanoPore and BioNanoFilter Quick Test technology, says in a news release that the research moves the company another step closer to making the technology available to women and newborns who are especially susceptible to strep infections.
According to NanoLogix, speed is of the essence when detecting Group B strep in mothers and infants. The release cites Centers for Disease Control statistics showing "25 percent of pregnant women may be colonized with Group B Strep. If colonized mothers give birth before antibiotics can be administered, the bacteria can be passed to the newborn and cause life-threatening blood infections, such as meningitis, sepsis, pneumonia or even still birth."
The new study was conducted at the University of Texas Health Science Center and published in the American Journal of Perinatology.
Begun more than 20 years ago as Infectech, the company for years focused on research and other endeavors, including alternative energy. Re-christened NanoLogix in 2005, the company quickly refocused on rapid detection testing.
Last year, the company signed a multi-year contract with the U.S. Environmental Protection Agency to develop rapid testing for bacterial threats to drinking water.
The company has also built a 2,800-square foot manufacturing facility in Hubbard to localize work being done elsewhere. Source: NanoLogix